News + Resources
Life Sciences Mergers and Acquisitions: A Vital Bridge Across the “Valley of Death”
Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is...
M&A Provides Vital Bridge for Life Science Innovation Amid Economic Headwinds, Market Demands
In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures.
In Case You Missed It: American Enterprise Institute Panelists Weigh in on FTC & DOJ’s Flawed Approach to Merger Enforcement
Following the public comment period on the FTC and DOJ's proposed merger guidelines, leading antitrust experts and economists expressed significant concerns about the dramatic shift in competition policy that the proposal represents. In a recent panel discussion...
U.S. Chamber of Commerce Survey: Regulators’ Proposed Approach to M&A Ignores Market Reality
A recent survey by the U.S Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s proposed approach to review and enforcement of mergers and acquisitions (M&A).
What They Are Saying: Proposed Premerger Review Rules Would Burden Life Sciences Innovators, Impede Vital New Therapies
In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.